drug
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
Marketedupdated 3mo agoby Novitium Pharma LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval382 co-mentions · 104 sources
- drugSYNALGOS-DC354 co-mentions · 107 sources
- drugaspirin335 co-mentions · 107 sources
- drugStem Cell Therapy for Coronavirus Disease 2019 (COVID-19)335 co-mentions · 107 sources
- tagSmall Molecule191 co-mentions · 104 sources
- drugcodeine127 co-mentions · 47 sources
- drugPROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE127 co-mentions · 47 sources
- drugPROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE127 co-mentions · 47 sources
all catalysts(30)
approval · 30
Jul 7, 1958
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Sep 6, 1983
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Sep 6, 1983
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Feb 3, 1987
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Aug 5, 1987
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Mar 5, 1999
approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Jun 7, 2001
approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Oct 31, 2001
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Jul 18, 2002
approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Mar 13, 2006
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
May 11, 2006
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
May 9, 2013
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Dec 16, 2016
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Aug 29, 2017
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Sep 18, 2018
approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Sep 18, 2018
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Sep 18, 2018
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Oct 7, 2019
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Apr 28, 2021
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Dec 4, 2023
approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Dec 4, 2023
approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Dec 15, 2023
approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Dec 15, 2023
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Oct 23, 2024
approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Oct 31, 2024
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Nov 21, 2024
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Nov 21, 2024
approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Apr 30, 2025
approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Dec 22, 2025
approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Dec 22, 2025
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Trials studying BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
- phase2Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy
- phase3Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
- N/AThromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization
- phase1Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Subjects
- N/AHighest Efficacy of Dual Antiplatelet Therapy After Carotid Artery Stenting in High Bleeding Risk Patients
- phase2Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
- phase2Mechanisms of Dupilumab in AERD
- phase1The Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ACI) in the Treatment of Acute Cerebral Infarction
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 2, 2033
~6.4 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Mar 13, 2033method-of-use (U-1902)US 9539214
- Mar 13, 2033method-of-use (U-1902)US 9539214
- Jan 2, 2033method-of-use (U-2324)US 9987231
- Jan 2, 2033method-of-use (U-2324)US 9987231
News(2)
- Dr Jones on the Protective Benefit and Tolerability of GLP-1 Agonists vs Aspirin for CRC PreventionColton Jones, MD, shares data from a retrospective analysis of GLP-1 receptor agonists vs aspirin for the primary prevention of colorectal cancer.onclive · 3mo ago
- Predicting consequences of new hepatitis B vaccine recsNew data on public trust in science, AI and mental health, and other news from Morning Roundsstat · 3mo ago
Data sources
last refreshed 39m ago
Found something off?
comments(0)
5-min edit window · permanent after that